Spots Global Cancer Trial Database for Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Official Title: Neoadjuvant-Adjuvant Versus Adjuvant-Only Therapy Combined With Endoscopic Surgery in Advanced Recurrent Nasopharyngeal Carcinoma:A Multicenter Randomized Controlled Trial

Study ID: NCT06235203

Conditions

Recurrent Nasopharyngeal Carcinoma

Interventions

endoscopic surgery

Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy

Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy

Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy

Study Description

Brief Summary: A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy

Detailed Description: Eligible patients are randomized into the control group and the experimental group. Patients in the experimental group would be administrated 2 courses of neoadjuvant therapy before surgery.After endoscopic surgery, patients would continue to receive 2-4 courses of chemotherapy and 8 courses of immunotherapy. Patients in the control group would firstly receive endoscopic surgery, followed by chemotherapy and immunotherapy. In total, 4 to 6 courses of chemotherapy and 10 courses of immunotherapy would be administrated.